Physician

Eric Michael Harris, D.O.

According to 2025 Medicare claims, Eric Harris, D.O. (NPI: 1902068158) practices hematology/oncology in the Deltona-Daytona Beach-Ormond Beach, FL market, with the plurality of this provider's patient population coming from Volusia, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32117-5122. Harris is affiliated with the Complete Health Accountable Care LLC (ACO ID: D0036), participating under the REACH model.

Harris' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 529 traditional Medicare patients, billed 142,778 HCPCS/CPT codes, and received $2,938,538 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,661 prescription claims across 339 beneficiaries totaling $3,767,893 in drug costs, led by Revlimid (Lenalidomide). DME data shows 61 claims. Open Payments data shows 141 records totaling $139,587. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $776,313 to $2,938,538. Similarly, Part D prescription costs have moved sharply higher in recent years, from $420,453 to $3,767,893. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	285	39,895	$776,313
2016	337	55,445	$1,360,495
2017	390	75,873	$2,070,973
2018	496	125,070	$2,447,276
2019	1,209	187,653	$3,330,637
2020	1,036	156,723	$3,818,034
2021	1,067	134,254	$3,163,604
2022	739	157,211	$3,458,912
2023	568	198,845	$3,674,302
2024	529	142,778	$2,938,538

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	101	724	$420,453
2016	125	916	$870,047
2017	154	1,071	$1,286,358
2018	186	1,290	$1,827,078
2019	211	1,279	$1,597,140
2020	200	1,212	$1,465,591
2021	286	1,569	$1,994,118
2022	302	1,688	$3,275,170
2023	302	1,657	$3,318,773
2024	339	1,661	$3,767,893

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	13	$508
2016	N/R	N/R	N/R
2017	N/R	39	$16,523
2018	N/R	99	$38,650
2019	N/R	75	$26,803
2020	N/R	60	$46,671
2021	N/R	61	$54,929
2022	N/R	11	$53
2023	N/R	N/R	N/R
2024	N/R	61	$1,900

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	234	661	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	250	402	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	175	285	$13
36415	Insertion of needle into vein for collection of blood sample	276	1,077	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	259	1,212	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	47	1,239	$712,933
Tasigna	Nilotinib Hcl	18	504	$363,591
Cabometyx	Cabozantinib S-Malate	12	360	$300,877
Pomalyst	Pomalidomide	12	336	$257,845
Xtandi	Enzalutamide	17	510	$238,573

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	22	$1,049
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	11	$500
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	28	$351

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	135	$2,664	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	6	$136,923	Mirati Therapeutics, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Eric Michael Harris, D.O.?

Tedicare shows public-source Medicare data for Eric Michael Harris, D.O. (NPI 1902068158), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Eric Michael Harris, D.O. have ACO affiliation data?

Eric Michael Harris, D.O. is shown with ACO affiliation data for Complete Health Accountable Care LLC (REACH, ACO ID D0036).

What billing organization is linked to Eric Michael Harris, D.O.?

Eric Michael Harris, D.O. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Eric Michael Harris, D.O. have Open Payments data?

Eric Michael Harris, D.O. has 141 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.